Susanna B. Park

Heterogeneity of phasic cholinergic signaling in neocortical neurons.

Assessment of nerve excitability in toxic and metabolic neuropathies.

Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.

Axonal ion channels from bench to bedside: a translational neuroscience perspective.

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.

Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy.

Acute, reversible axonal energy failure during stroke-like episodes in MELAS.

Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.

Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.

The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.

Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?

Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.

Purple pigments: the pathophysiology of acute porphyric neuropathy.

Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy.

Activity-dependent conduction failure: molecular insights.

Longitudinal assessment of oxaliplatin-induced neuropathy.

Impact of oxaliplatin-induced neuropathy: a patient perspective.

Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes.